

This listing of claims will replace all prior versions of claims in the application.

Claim 1. (original) A method for administering a therapeutic medium to a posterior segment of an eye, the method comprising the step of:
instilling the therapeutic medium sub-retinally.

Claim 2. (original) The administering method of claim 1, wherein said step of instilling includes localizing the action of the therapeutic medium at the choroid and the retina and minimizing action at other tissues of the eye.

Claim 3. (original) The administering method of claim 1, wherein the therapeutic medium being administered is one of a drug, medicament, antiproliferative, neuroprotective, steroidal anti-inflammatory, non-steroidal anti-inflammatory, growth factor, neurotropic factor, antiangiogenic, thrombolytic or a gene.

Claim 4. (original) The administering method of claim 3, wherein the steroidal anti-inflammatory is selected from the group consisting of triamcinolone, dexamethasone, fluocinolone, cortisone, prednisolone, flumetholone, and derivatives thereof.

Claim 5. (original) The administering method of claim 1, wherein a disease state to be treated is selected from the group consisting of ocular neovascularization, ocular inflammation and retinal degeneration.

Claim 6. (original) The administering method of claim 1, wherein said step of instilling includes forming a depot of a drug between the choroid and the retina.

Claim 7. (original) The administering method of claim 1, wherein said step of instilling includes one of injecting or implanting the therapeutic medium sub-retinally.

Claim 8. (original) The administering method of claim 7, wherein said step of instilling includes injecting a solution including the therapeutic medium between the choroid and the retina.

Claim 9. (original) The administering method of claim 1, wherein said step of instilling includes instilling the therapeutic medium in a sub-retinal space.

Claim 10. (original) The administering method of claim 1, wherein the therapeutic medium comprises a sustained release device and wherein said step of instilling includes implanting the sustained release device in a sub-retinal space.

Claim 11. (original) The administering method of claim 1, wherein said step of instilling includes:

creating a localized retinal detachment to define a sub-retinal space; and
disposing the therapeutic medium in the sub-retinal space formed by the localized retinal detachment.

Claim 12. (original) The administering method of claim 11, wherein said disposing includes one of injecting or implanting the therapeutic medium in the sub-retinal space formed by the retinal detachment.

Claim 13. (original) The administering method of claim 12, wherein said injecting includes injecting a solution including the therapeutic medium in the sub-retinal space.

Claim 14. (original) The administering method of claim 12, wherein the therapeutic medium comprises a sustained release device and wherein said step of implanting includes implanting the sustained release device in the sub-retinal space.

Claim 15. The administering method of claim 14, wherein the sustained release device is configured to provide a sustained sub-retinal release of the therapeutic medium.

Claim 16. (original) The administering method of claim 10, wherein the sustained release device is configured to provide a sustained sub-retinal release of the therapeutic medium.

Claim 17. (currently amended) The administering method of ~~claim 15~~ any of claim ~~15 or 16~~, wherein the therapeutic medium is one of a drug, medicament, antiproliferative, neuroprotective, steroidal anti-inflammatory, non-steroidal anti-inflammatory, growth factor, neurotropic factor, antiangiogenic, thromolytic or a gene.

Claim 18. (original) The administering method of claim 17, wherein the steroidal anti-inflammatory is selected from the group consisting of triamcinolone, dexamethasone, fluocinolone, cortisone, prednisolone, flumetholone, and derivatives thereof.

Claim 19. (original) The administering method of claim 11, wherein a disease state to be treated is selected from the group consisting of ocular neovascularization, ocular inflammation and retinal degeneration.

Claim 20. (original) A method for treating an eye, comprising the step of: administering a therapeutic medium to a posterior segment of an eye sub-retinally.

Claims 21-24. (cancelled)

Claim 25. (original) The eye treatment method of claim 20, wherein said step of administering includes:

forming a sub-retinal space; and

disposing the therapeutic medium in the sub-retinal space.

Claim 26. (currently amended) The eye treatment method of ~~claim 24~~ any of claims 24-25, wherein said step of disposing includes:

injecting a solution including the therapeutic medium into the sub-retinal space.

Claim 27. (original) The eye treatment method of claim 20, further comprising the step of controllably releasing the over time the sub-retinally administered therapeutic medium.

Claim 28. (original) The administering method of claim 1, further comprising the step of controllably releasing over time the sub-retinally instilled therapeutic medium.

Claim 28A. (cancelled)

Claim 29. (original) A method for administering a steroid to a posterior segment of an eye, the method comprising the step of:
instilling the steroid sub-retinally.

Claim 30. (original) The administering method of claim 29, wherein said step of instilling includes localizing the action of the steroid at the choroid and the retina and minimizing action at other tissues of the eye.

Claims 31-44A. (cancelled)

Claim 45. (original) A method for treating an eye, comprising the step of:
administering a steroid to a posterior segment of an eye sub-retinally.

Claim 46. (original) The eye treatment method of claim 45, wherein said step of administering sub-retinally includes forming a depot of a drug between the choroid and the retina.

Claims 47-57. (cancelled)